The Jenex Corporation reported that the development of the working prototype for the patent pending TherOZapTM is progressing well and expected to be completed in 4 to 6 weeks. On December 8 2016, the company announced the development of its TherOZapTM device utilizing proprietary features would be tested against both the Zika and West Nile Virus. Jenex is now in the final stages of design work which includes technical advances such as the selection of optimal components and form factor. The company expects to initiate testing of the working prototype by a world renowned scientific research lab against the Zika and the West Nile virus towards the end of the first quarter of 2017. The scientific lab testing would be comprised of in-vitro tests to determine if TherOZapTM is effective in inactivating both the Zika and West Nile virus and potentially other mosquito borne diseases. In addition the lab testing will determine any anti-viral, anti-microbial and anti-inflammatory benefits of the device. The tests will determine if the Zika and West Nile virus' are susceptible to the treatment conditions of the technology including the identification of effective treatment parameter ranges. Following the in-vitro tests and provided the results are favorable the company will undergo further testing of the device.